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FLAVOCOXID ACTS VIA AN ANTI-PEROXIDASE ACTIVITY ON
CYCLOOXYGENASE ENZYMES, 5-LIPOXYGENASE INHIBITION AND A
STRONG ANTIOXIDANT ACTIVITY TO MANAGE OSTEOARTHRITIS
B.P. Burnett1, L. Pillai1, A. Bitto2, F. Squadrito2, R.M. Levy1
1Primus Pharmaceuticals, Inc., Scottsdale, AZ; 2Universtiy of Messina, Messina,
Italy
Purpose: Flavocoxid, a USFDA-regulated, prescription medical food for the
clinical dietary management of osteoarthritis (OA) under the supervision
of a physician, shows equivalent eﬃcacy to NSAIDs in clinical studies
with fewer side effects. Its exact mechanism of action, however, is poorly
understood. The aim of these studies is to characterize ﬂavocoxid’s per-
oxidase/cyclooxygenase inhibition of cyclooxygenase-1 (COX-1) and COX-2
as well as its anti-5-lipoxygenase (5-LOX) activity. In addition, ﬂavocoxid’s
antioxidant capacity is determined along with its effect on inducible
inﬂammatory gene expression.
Methods: Puriﬁed enzymes were used to assess ﬂavocoxid’s anti-
peroxidase and anti-cyclooxygenase activity on COX-1 and COX-2 as
well as inhibitory activity on 5-LOX. Multiple standard antioxidant assay
assays were utilized to judge ﬂavocoxid’s antioxidant capacity and cell
co-culture of LPS-stimulated human peripheral blood mononuclear cells
(PBMCs) with ﬂavocoxid for its effect on inducible inﬂammatory gene
expression of COX-2, interleukin-1beta (IL-1β), IL-6 and tumor necrosis
factor-alpha (TNFα) as well as nuclear factor-kappa B (NF-κB).
Results: Flavocoxid showed balanced inhibition of COX-1 and COX-
2 peroxidase activities with inhibitory concentrations (IC50s) of 12.3
and 11.3μg/ml, respectively, while the 5-LOX IC50 was 110μg/ml. No
detectable 5-LOX inhibition was found for rofecoxib, celecoxib, valde-
coxib, diclofenac, meloxicam, naproxen, ibuprofen or aspirin. Flavo-
coxid showed minimal inhibition of cyclooxygenase activity for COX-1
(IC50=25μg/ml) compared to indomethacin (IC50=0.012μg/ml) and no
detectable cyclooxygenase inhibition of COX-2 compared to NS-398
(IC50=0.095μg/ml). Flavocoxid also demonstrated a strong antioxidant
capacity against a variety of reactive oxygen species: oxygen radical
absorbance capacity, ORAChydro=3700 μmolTE/g; ORAClipo= 19μmolTE/g;
ferric reducing/antioxidant power, FRAP=1145μmolTE/g; hydroxyl radi-
cal absorbance capacity, HORAC= 1326μmolCAE/g; peroxynitrite radical
averting capacity, NORAC=1936μmolTE/g; superoxide radical averting ca-
pacity, SORAC= 27kunitSODeq/g; trolox equivalent antioxidant capacity,
TEAC=2456μmolTE/g; and 2,2-di(4-tert-octylphenyl)-1-picrylhydroxyl ca-
pacity, DPPH=767μmolTE/g. In lipopolysaccharide-stimulated PBMCs, ﬂavo-
coxid strongly reduced gene expression of COX-2 (80-fold), TNFα (11-fold),
IL-1β (10-fold) and IL-6 (40-fold) and, to a lesser extent, COX-1 (2.8-fold).
Expression of NF-κB gene was also reduced (2.2-fold).
Conclusions: These results suggest that the clinically favorable effects
and equivalency to NSAIDs in the management of OA are more than
likely achieved by simultaneous modiﬁcation at multiple points in the
inﬂammatory process making ﬂavocoxid a unique anti-inﬂammatory acting
via antioxidant mechanisms both on the cyclooxygenase enzyme and in
damping inducible, inﬂammatory gene expression. Flavocoxid also acts
through direct inhibition of 5-LOX to avoid a shunting of arachidonic acid
metabolism toward leukotriene production.
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Purpose: The purpose of this study was to determine the frequency of
prescription and the changes in prescribing patterns within the total cohort
and three sub-cohorts of the OAI study.
Methods: Information was collected at baseline, 12, 24 and 36 month clinic
visits and medication data were sorted by major drug classes, focussing
on NSAIDs, Statins and Bisphosphonates, chosen as they are known to
be associated with musculoskeletal diseases in each of the three cohorts
(Progression, Incidence and Control). Chi-squared statistics were used to
compare groups at baseline and 36 months.
Results: All cohorts contained more women than men and women were
prescribed more items than men at all timepoints and in all cohorts except
the control cohort at 36 months.
Figure 1 shows the major trends between cohorts and over time. Analysis
Figure 1
showed a signiﬁcant increase in prescriptions of Statins from baseline to
3 years follow-up (from 26% to 36% of total cohort [n=4796 at baseline]
(P<0.0001)). Atorvastatin prescription numbers did not change but there
were increases in Simvastatin and Lovostatin prescription numbers in both
the Progression and Incidence cohorts over time. There was a signiﬁcant
reduction in prescription of NSAIDs (P<0.05) although there was a 12.5%
reduction in prescriptions of Alendronate.There was a decreasing trend
for the prescription of anti-depressant drugs. This was noticeable in the
prescriptions of Fluoxetine and Paroxetine which both decreased over
time. Three subjects were noted to be on antiretroviral medication which,
according to the FDA list of side effects, can result in severe bone loss.
Opioid drug prescriptions did not change signiﬁcantly over time.
The proportion of medications prescribed for each cohort varied signiﬁ-
cantly for each of the three drug groups (P<0.001). Fewer Bisphosphonates
were prescribed in the Progression group (7%) compared to the Incidence
(11%) or Control (10%) groups. Both Statin and NSAID prescriptions were
highest in the Progression group (28% and 39% respectively), followed by
the Incidence (26% and 26%) and Control groups (11% and 9%).
Conclusions: During the 3 years of this study, prescriptions of Statins
signiﬁcantly increased, NSAID prescriptions signiﬁcantly decreased whilst
Bisphosphonate prescriptions remained stable. The increase in prescrip-
tions of Statins may reﬂect a general rise in the tendency to prescribe
this medication in the ‘normal’ population. The reduction in COX-2 speciﬁc
NSAIDS may be due to the withdrawal of Rofecoxib and limitations placed
on the prescription of other COX-2 inhibitors.
There are drugs which we have considered under their major drug classi-
ﬁcation which may be prescribed for other purposes, such as Gabapentin
which has been classiﬁed as treatment for epilepsy but can also be
prescribed for severe neuropathic pain.
The changes in prescription use between the cohorts and over time should
be borne in mind for all analysis. Bisphosphonate use is of particular
interest, as it shows a large number of the cohort (over 450 subjects) are
taking medication designed to increase bone density which may affect their
OA status and progression in unknown ways.
567
ANTI-INFLAMMATORY ACTIVITY OF AN ETHANOLIC CAESALPINIA SAPPAN
EXTRACT IN HUMAN CHONDROCYTES IN VITRO
S. Wu1, F. Unger1, M. Goldring2, H. Viernstein1, S. Toegel1
1Dept. of Pharmaceutical Technology and Biopharmaceutics, Vienna, Austria;
2Hosp. for Special Surgery, Weill Cornell Med. Coll., New York, NY
Purpose: Extracts from Caesalpinia sappan as well as their main con-
stituents have been reported to exhibit anti-inﬂammatory, antioxidant,
antibacterial and immunosuppressive activities in different tissues. Given
their inhibitory effect on inﬂammatory cytokines and mediators, compo-
nents of Caesalpinia sappan might be potential drug candidates for disease
modiﬁcation in osteoarthritis (OA). The aim of this study was to evaluate
the anti-inﬂammatory effects of an ethanolic extract from Caesalpinia
sappan (CSE) in an osteoarthritic chondrocyte model.
Methods: CSE was prepared by continuous extraction with ethanol for
24 h. The quality and stability of CSE from different batches was veriﬁed
